Last panel at #pmconf: Mike Pellini, MD "Dx should be the backbone of #personalizedmedicine " yet policy stymieing investment

Michael Reitermann: We're somewhere between evolution and revolution of patient care. Patient is number one. #PMConf #genomics

.Foundation Medicine Pellini: There's no "if" only "when & how" #genetic testing will become the norm, payers will cover Dx #PMConf

.N-of-One is an example says Cournoyer! She was told there's no such thing as a molecular decision support company x.com/SamBaxterCGC/s…

.Siemens Healthineers Michael Reitermann shares stats on errors in diagnostics from recent NASEM Health report bit.ly/1j9QxmX #PMConf

.Regeneron Geisinger study #genetics info w/ 2 separate but complimentary goals: new therapies, better decision making #PMConf

Ability to send samples btwn countries instead of sequencing in country, sending data is big biz dev opp Siemens Healthineers Reitermann #PMConf

Yancopoulos Regeneron on importance of basic research that precedes translational achievements #PMConf

.@PMCAmy from audience: Sometimes payer responses to Dx are irresponsible, arbitrary. Need to join together, come up w/ solutions #PMConf

Yancopoulos: Cutting R&D is short-sighted. Need to elevate long-term view, have strong research, innovation, investment, prevention #PMConf

MP: Overall, we are here to impact the care of the patient and to help them fight cancer. #PMConf

Thank you! We're looking forward to his keynote. #PMConf x.com/AstraZenecaUS/…

“We need to move from treating the disease, to treating the mutation, to treating the individual” Paul Hudson #PMconf

.AstraZenecaUS Hudson: Still only 500 treatments for 7,000 known diseases. Continued collab. needed to reach more patients #PMConf

Paul Hudson AstraZenecaUS: Testing for #genetic mutations in #cancer can be as easy as testing glucose levels today #PMConf

PH: It's about breakthrough science and collaboration rather than who can get there first. AstraZenecaUS #PMConf

.AstraZenecaUS Hudson: We need to look beyond disease states, see patients as partners not data points. #PMConf

.Harvard Medical School Kucherlapati sums up 2015 #PMConf: It's not whether #personalizedmedicine is here to stay but how fast it’s being implemented

Key themes: Prevention, physician ed, pricing, partnerships, protocols & of course – patients – are future of #personalizedmedicine #PMConf

Another great #PMConf for the books – thanks to all who joined us! We’ll see you next year!